"Demand for skilled medtech professionals in the Asia Pacific region is growing rapidly"

2024 saw Japanese medtech firm Olympus receiving approval for the company's first cloud-based AI endoscopy devices in the US and Europe, marking a significant milestone in Olympus' efforts to enhance clinical outcomes and operational efficiency in endoscopy, paving the way to launch its upcoming endoscopy solution, the “Intelligent Endoscopy Ecosystem”.

- Dr Manbeena Chawla

Marc Radatt, Chief Executive Officer, Olympus Corporation Asia Pacific, Singapore

The estimated revenue and annual growth rate during the fiscal year ending March 2025 of Olympus Corporation is approximately 1,009 billion yen/ 9 percent. To find out more about the company's strategic growth plans in the new year, BioSpectrum Asia interacted with Marc Radatt, Chief Executive Officer of Olympus Corporation Asia Pacific, Singapore. Edited excerpts:

Could you please share some details of the company's investment plans, and new product development in the coming years?

In emerging markets, demand for medical devices is growing due to rapidly increasing populations, lifestyle changes resulting from economic growth, and the expansion of medical infrastructures. The need for gastrointestinal (GI) endoscopes, which contribute to the early detection and treatment of GI cancers, is increasing as the incidence of cancer is expected to rise in the future. Conversely, emerging markets are facing a shortage of highly specialised endoscopists. Therefore, we will continue to increase our investment in training activities for endoscopists in these regions.

Following the establishment of a direct subsidiary in Indonesia in 2024, we will continue to focus our efforts on building our profile and collaborate with healthcare professionals (HCPs) to enhance patient outcomes and access to healthcare in this growing market. In light of the ongoing healthcare reforms across Southeast Asia, we are committed to working closely with HCPs across our region to advance healthcare through our ongoing professional training programmes. In addition, we will continue to roll out key products to various markets in the region across our gastrointestinal, respiratory, and urology portfolios by the fiscal year ending March 2026.